CARsgen Claims First Clinical Win For CLDN 18.2 CAR-T In G/GEJ Adenocarcinoma

 
• By Dexter Jie Yan

CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
Satri-cel is the world's first CAR-T cell therapy candidate that has reported positive results in a pivotal clinical trial for solid tumors. • Source: Shutterstock

More from Cell Therapies

More from Focus On Asia